Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

EPT Disclosure

8 Apr 2010 08:33

RNS Number : 8769J
Piper Jaffray Ltd
08 April 2010
 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

 

 

1. KEY INFORMATION

 

Name of exempt principal trader

Piper Jaffray Ltd.

Company dealt in

Ark Therapeutics Group plc 

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ord 1p

Date of dealing

07 April 2010

 

 

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

 

 

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

425,000 0.20%

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

 

Total

 

425,000 0.20%

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

 

Class of relevant security:

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

 

Total

 

 

(c) Rights to subscribe (Note 2)

 

Class of relevant security:

 

Details

 

 

3. DEALINGS (Note 3)

 

(a) Purchases and sales

 

Purchase/sale

 

Number of securities

Price per unit (Note 4)

Buy

1,992

9.53p

Buy

45,000

10.00p

Sell

7,188

10.25p

Buy

20,000

10.50p

 

 

(b) Derivatives transactions (other than options)

 

Product name,

e.g. CFD

Long/short (Note 5)

Number of securities (Note 6)

Price per unit (Note 4)

 

 

 

 

 

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 6)

Exercise

price

Type, e.g. American, European etc.

Expiry

date

Option money

paid/received per unit (Note 4)

 

 

(ii) Exercising

 

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 4)

 

 

 

 

(d) Other dealings (including new securities) (Note 3)

 

Nature of transaction (Note 7)

 

Details

Price per unit (if applicable) (Note 4)

 

 

 

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached? (Note 8) NO

 

 

Date of disclosure

08 April 2010

Contact name

Norman Gould

Telephone number

020 3142 8780

Name of offeree/offeror with which connected

Ark Therapeutics Group plc 

Nature of connection (Note 9)

Adviser and broker

 

 

Notes

 

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMUWOBRRAASRRR
Date   Source Headline
22nd Apr 20093:34 pmRNSAGM Results
7th Apr 200911:09 amRNSAnnual Information Update
7th Apr 20097:00 amRNSResearch Update
17th Mar 20095:03 pmRNSHolding(s) in Company
13th Mar 20094:25 pmRNSHolding(s) in Company
11th Mar 20097:00 amRNSFinal Results
2nd Mar 200911:21 amRNSVoting Rights and Capital
26th Feb 20097:00 amRNSPatent Filing
17th Feb 20092:14 pmRNSHolding(s) in Company
16th Feb 20095:39 pmRNSHolding(s) in Company
16th Feb 20097:00 amRNSResearch Update
5th Feb 200910:50 amRNSDealing by Employee Benefit Trust
2nd Feb 20097:00 amRNSDirector/PDMR Shareholding
21st Jan 20094:40 pmRNSSecond Price Monitoring Extn
21st Jan 20094:37 pmRNSPrice Monitoring Extension
21st Jan 200912:12 pmRNSNotice of Results
14th Jan 20097:00 amRNSRe Agreement
9th Jan 200910:23 amRNSHolding(s) in Company
8th Jan 20097:00 amRNSTrinam Phase III trial to commence
6th Jan 20097:00 amRNSResearch Update
31st Dec 20089:00 amRNSTotal Voting Rights
16th Dec 20083:46 pmRNSNotification of Major Interests in Shares
9th Dec 20084:40 pmRNSSecond Price Monitoring Extn
9th Dec 20084:35 pmRNSPrice Monitoring Extension
9th Dec 20087:00 amRNSRegulatory Approval
5th Dec 20082:28 pmRNSBlocklisting Six Monthly Return
1st Dec 20087:00 amRNSRegulatory Application
24th Nov 200811:58 amRNSDirector/PDMR Shareholding
13th Nov 20087:00 amRNSInterim Management Statement
20th Oct 20087:00 amRNSProduct Launch
2nd Oct 20087:00 amRNSArk secures reimbursement for Neuropad
30th Sep 20085:06 pmRNSVoting Rights and Capital
17th Sep 20081:08 pmRNSHolding(s) in Company
27th Aug 20087:00 amRNSInterim Results
27th Aug 20087:00 amRNSResearch Update
26th Aug 20084:08 pmRNSHolding(s) in Company
1st Aug 200810:47 amRNSVoting Rights and Captial
31st Jul 20081:12 pmRNSHolding(s) in Company
30th Jul 20087:00 amRNSResearch Update
16th Jul 20087:00 amRNSResearch Update
8th Jul 200811:00 amRNSArk opens new manufacturing f
24th Jun 200811:28 amRNSHolding(s) in Company
18th Jun 20087:00 amRNSResearch Update
6th Jun 200812:10 pmRNSBlocklisting Application
3rd Jun 200810:58 amRNSBlocklisting Interim Review
3rd Jun 200810:51 amRNSBlocklisting Interim Review
2nd Jun 20087:00 amRNSRegulatory Approval
30th May 20084:52 pmRNSVoting Rights and Capital
30th May 20087:00 amRNSResearch Update
22nd May 20081:27 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.